Synlogic, Inc. (SYBX) stock
SYBXOTCPharmaceutical PreparationsFiscal year ends December 31
$1.07+0.07 (+7.00%)
Close on Oct 19, 2026Market cap $13.29MP/E –Yield –
Synlogic EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Synlogic's EPS for the twelve months ending Sep 30, 2026 was -$0.18. For fiscal 2025 it was -$0.08. The highest annual figure on record is -$0.08 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.08 | – |
| FY2024 | Dec 31, 2024 | -$1.92 | – |
| FY2023 | Dec 31, 2023 | -$9.42 | – |
| FY2022 | Dec 31, 2022 | -$13.83 | – |
| FY2021 | Dec 31, 2021 | -$16.35 | – |
| FY2020 | Dec 31, 2020 | -$24.75 | – |
| FY2019 | Dec 31, 2019 | -$25.50 | – |
| FY2018 | Dec 31, 2018 | -$30.45 | – |
| FY2017 | Dec 31, 2017 | -$90.00 | – |
| FY2016 | Dec 31, 2016 | -$137.03 | – |
| FY2015 | Dec 31, 2015 | -$636.19 | – |
| FY2014 | Dec 31, 2014 | -$31646.25 | – |
| FY2013 | Dec 31, 2013 | -$479440.69 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.31 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.04 | – |
| Q1 FY2026 | Mar 31, 2026 | $0.05 | +66.7% |
| Q4 FY2025 | Dec 31, 2025 | $0.12 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.19 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.04 | -116.0% |
| Q1 FY2025 | Mar 31, 2025 | $0.03 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.06 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.01 | – |
| Q2 FY2024 | Jun 30, 2024 | $0.25 | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.11 | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.54 | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.57 | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.21 | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.39 | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.54 | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.73 | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.30 | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.30 | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.14 | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.35 | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.20 | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.40 | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.85 | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.40 | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.60 | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.90 | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.55 | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.85 | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.75 | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.65 | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.05 | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.45 | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.85 | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.25 | – |
| Q4 FY2017 | Dec 31, 2017 | -$11.10 | – |
| Q3 FY2017 | Sep 30, 2017 | -$24.90 | – |
| Q2 FY2017 | Jun 30, 2017 | -$70.50 | – |
| Q1 FY2017 | Mar 31, 2017 | -$26.10 | – |
| Q4 FY2016 | Dec 31, 2016 | -$45.67 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?